Abstract: Provided are an anti-4-1BB antibody, an antigen-binding fragment thereof and medical use thereof. Further, provided are a chimeric antibody and a humanized antibody comprising a CDR region of the anti-4-1BB antibody, as well as a pharmaceutical composition comprising a human anti-4-1BB antibody or an antigen-binding fragments thereof, and use thereof as anti-cancer medicaments. In particular, provided is use of a humanized anti-4-1BB antibody in the preparation of a medicament for the treatment of diseases or conditions mediated by 4-1BB.

Abstract: The present invention relates to a ligand-drug conjugate of an exatecan analogue, a preparation method therefor and an application thereof. Specifically, the present invention provides a ligand-drug conjugate having a structure shown in formula (-D), a preparation method therefor, a pharmaceutical composition containing same, and use thereof in preparation of drugs for treating cancers by means of receptor regulation. The definition of each substituent in formula (-D) is the same as that in the description.

Abstract: The present invention provides an anti-ox40 antibody, an antigen-binding fragment thereof, and the pharmaceutical use. Further, the present application provides a chimeric antibody and a humanized antibody, the chimeric antibody and the humanized antibody comprising a CDR region from the anti-OX40 antibody and the antigen-binding fragment thereof, and also provides a pharmaceutical composition comprising the anti-OX40 antibody and the antigen-binding fragment thereof, and the use thereof as a drug for treating cancers.

Abstract: Provided are a LAG-3 antibody, an antigen-binding fragment thereof, and a pharmaceutical application thereof. Further, provided are a chimeric antibody comprising a CDR of the LAG-3 antibody, a humanized antibody, a pharmaceutical composition comprising the LAG-3 antibody and the antigen-binding fragment thereof, and an application of the pharmaceutical composition as an antineoplastic drug. Particularly, provided is an application of a humanized LAG-3 antibody in preparation of drugs for treatment of diseases involving immune cells.

Abstract: The present disclosure relates to a human IL-4R binding antibody, an antigen binding fragment thereof, and a medical use thereof. Provided are a chimeric antibody and a humanized antibody, including a CDR region from a human IL-4R binding antibody and an antigen binding fragment thereof, a pharmaceutical composition including the human IL-4R binding antibody and the antigen binding fragment thereof, and a use thereof as a drug treating allergic disease. Also provided is a use of the humanized antibody IL-4R binding antibody in preparing a drug used for treating IL-4R mediated diseases or illnesses.

Abstract: This application describes a use of an EZH2 inhibitor combined with a BTK inhibitor in preparing a drug for treating a tumor is described.

Abstract: Provided in the present invention is a use of CDK4/6 inhibitor in combination with EGFR inhibitor in the preparation of a medicament for treating tumor diseases. In particular, provided in the invention is a use of a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) in combination with a human epidermal growth factor receptor inhibitor (EGFRi) for the preparation of a medicament for preventing or treating tumor diseases.

Abstract: A combination of a VEGFR inhibitor and a PARP inhibitor is described. In particular, this combination can be used in the preparation of a medicament for treating gastric cancer.

Abstract: An interleukin 15 (IL-15) protein complex is provided. The IL-15 protein complex includes soluble fusion proteins (I) and (II), wherein the fusion protein (I) is an IL-15 polypeptide or a functional fragment thereof, and the soluble fusion protein (II) is an IL-15R? polypeptide or a functional fragment thereof. The soluble fusion protein (I) has at least one amino acid residue mutated to a cysteine (Cys) residue, which pairs with a corresponding mutated Cys residue on the soluble fusion protein (II), or vice versa, to form one or more disulfide bonds. The IL-15 protein complex can be used for tumor therapy.

Abstract: A B7-H3 antibody, an antigen-binding fragment thereof and a medical use thereof are provided. Furthermore, a pharmaceutical composition containing the B7-H3 antibody or antigen-binding fragment thereof, and the use thereof as a medicament are provided. In particular, a use of a human B7-H3 antibody or antigen-binding fragment thereof for the manufacture of a medicament for the treatment of a B7-H3-associated disease or condition are described.

Abstract: This application describes a use of an EZH2 inhibitor combined with a BTK inhibitor in preparing a drug for treating a tumor is described.

Abstract: An interleukin 15 (IL-15) protein complex is provided. The IL-15 protein complex includes soluble fusion proteins (I) and (II), wherein the fusion protein (I) is an IL-15 polypeptide or a functional fragment thereof, and the soluble fusion protein (II) is an IL-15R? polypeptide or a functional fragment thereof. The soluble fusion protein (I) has at least one amino acid residue mutated to a cysteine (Cys) residue, which pairs with a corresponding mutated Cys residue on the soluble fusion protein (II), or vice versa, to form one or more disulfide bonds. The IL-15 protein complex can be used for tumor therapy.

Abstract: A B7-H3 antibody, an antigen-binding fragment thereof and a medical use thereof are provided. Furthermore, a pharmaceutical composition containing the B7-H3 antibody or antigen-binding fragment thereof, and the use thereof as a medicament are provided. In particular, a use of a human B7-H3 antibody or antigen-binding fragment thereof for the manufacture of a medicament for the treatment of a B7-H3-associated disease or condition are described.

Abstract: The present invention provides an anti-CD27 antibody, an antigen-binding fragment thereof, and a medical use thereof. Specifically, the present invention provides a human antibody comprising the CDR region of the anti-CD27 antibody, and a pharmaceutical composition comprising the human anti-CD27 antibody and an antigen-binding fragment thereof, and a use thereof as an anticancer drug. In particular, the invention provides a human anti-CD27 antibody and a use thereof in the preparation of a drug for the treatment of CD27-mediated diseases or disorders.

Abstract: A stable anti-PD-1 antibody pharmaceutical preparation and an application thereof in a medicine. The anti-PD-1 antibody pharmaceutical preparation comprises an anti-PD-1 antibody, a buffer, and can further comprise at least one type of stabilizer, and optionally can further con a surfactant. The anti-PD-1 antibody pharmaceutical preparation of the present invention can effectively suppress antibody aggregation and deamidation, thereby preventing degradation of an antibody product, obtaining a stable injected pharmaceutical preparation.

Abstract: The present invention relates to a PD-L1 antibody, antigen-binding fragments, and medical application thereof. Further, the present invention relates to chimeric antibodies and humanized antibodies comprising the CDR regions of the present PD-L1 antibody, as well as a pharmaceutical composition comprising the present PD-L1 antibody and the antigen-binding fragments thereof, and their use as anti-cancer drugs. In particular, the present invention relates to a humanized PD-L1 antibody and its use in preparation of a medicament for the treatment of PD-L1 mediated disease or disorder.

Abstract: A method for preventing or treating tumor diseases with a combination of a tyrosine kinase inhibitor and a CDK4/6 inhibitor is provided. In particular, a method for preventing or treating tumor diseases, including administering to a patient a tyrosine kinase inhibitor of a compound of formula (I), or a complex, a pharmaceutically acceptable salt or a stereoisomer thereof and a CDK4/6 inhibitor is provided.

Abstract: Disclosed is the use of a KOR agonist in combination with a MOR agonist in preparing a drug for treating pain. The KOR agonist is selected from a compound as shown in the general formula (I), and the MOR agonist is selected from a compound as shown in the general formula (II), wherein the definitions of each substituent in the general formula (I) and (II) are the same as defined in the description.

Abstract: The present invention relates to a PD-L1 antibody, antigen-binding fragments, and medical application thereof. Further, the present invention relates to chimeric antibodies and humanized antibodies comprising the CDR regions of the present PD-L1 antibody, as well as a pharmaceutical composition comprising the present PD-L1 antibody and the antigen-binding fragments thereof, and their use as anti-cancer drugs. In particular, the present invention relates to a humanized PD-L1 antibody and its use in preparation of a medicament for the treatment of PD-L1 mediated disease or disorder.

Abstract: The present invention provides a PCSK9 antibody, an antigen-binding fragment thereof, and a medicinal application thereof. Provided in the invention is a chimeric antibody and a humanized antibody, both comprising a CDR of the PCSK9 antibody, and a pharmaceutical composition comprising the PCSK9 antibody and an antigen-binding fragment thereof, and an application of the PCSK9 antibody as a lipid-lowering agent. The invention specifically relates to an application of a humanized PCSK9 antibody for preparing a pharmaceutical drug to treat a PCSK9-induced disease or symptom.